THANK YOU FOR SUBSCRIBING
ImmunoScape specializes in deep profiling of immune cells and identification of antigen-specific T cells. The company enables pharmaceutical and biotechnologies companies to gain insights from clinical trial patient data and to develop more effective immunotherapies
FREMONT, CA: Singapore-based biotech firm enabling insights into the human immune system, ImmunoScape secured USD 11 million in an equity financing round led by U.S. based venture firm Anzu Partners, with participation from University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia. The company's immune profiling platform, which enables deep insights into the T-cells of the human immune system, has already been intensely engaged in COVID-19 related programs across three different continents.
"There is an urgent need to understand how the T-cell immune response contributes to COVID-19 immunity and can be leveraged for vaccine design," said ImmunoScape co-founder and Chief Operating Officer Dr Alessandra Nardin. "In global collaborations with Massachusetts General Hospital, University of Parma (Italy), and Duke-NUS, we are evaluating COVID-19 patients and recovered individuals. We are building a large data set on human T-cell response to COVID-19, in an effort to develop new therapies and better vaccines with our partners."
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
ImmunoScape specializes in deep profiling of immune cells and identification of antigen-specific T cells. The company enables pharmaceutical and biotechnologies companies to gain insights from clinical trial patient data and to develop more effective immunotherapies. The company has established collaborations with various vaccine development companies, including the San Diego-based Arcturus which is running clinical trials in Singapore. The technology was based on work begun at Stanford University and continued at A*STAR of Singapore, where the company was established in 2017.
"As a Singapore-based firm supported by the Agency for Science Technology and Research (A*STAR), our team has deep experience assessing T-cell immune response to dengue, hepatitis B, and other viruses. It was clear that we must provide deep support to COVID-19 vaccine development in this global crisis," said ImmunoScape co-founder and CEO Choon Peng Ng, formerly a senior executive at A*STAR.
ImmunoScape aims to continue its core mission of enabling advanced immunotherapies for cancer, an area where its scientific track record is solid. "In 2019 we co-authored a paper together with collaborators at Genentech illustrating the role of our technology in evaluating checkpoint blockade immunotherapies," said Dr Nardin. "The interest in those insights attracted global attention and encouraged us to seek financing to expand further into the U.S. market."
More in News